Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study

Abstract HLX01 (HanliKang®) is a rituximab biosimilar that showed bioequivalence to reference rituximab in untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) in the phase 3 HLX01-NHL03 study. Here, we report the 5-year follow-up results from the open-label extension part. Patients were ra...

全面介紹

書目詳細資料

Principais autores:	Yan Qin, Yongping Song, Dong Wang, Ou Bai, Jifeng Feng, Xiuhua Sun, Lihua Qiu, Jianmin Yang, Yu Yang, Zhao Wang, Jianda Hu, Huaqing Wang, Hang Su, Zhengming Jin, Wenbin Qian, Chuan Jin, Mingzhi Zhang, Ding Yu, Li Liu, Guoan Chen, Yarong Li, Tao Sun, Jie Jin, Huizheng Bao, Xin Du, Hui Zhou, Gan Fu, Yuankai Shi
格式:	Artigo
語言:	Inglês
出版:	BMC 2024-01-01
叢編:	BMC Cancer
主題:	HLX01 Rituximab biosimilar DLBCL Overall survival HanliKang®
在線閱讀:	https://doi.org/10.1186/s12885-024-11876-9
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!